Comparison of cytogenetic responses in newly diagnosed chronic phase chronic myelogenous leukemia (CML) patients.
| . | Cytogenetic Responses† . | |||
|---|---|---|---|---|
| . | 6 months . | 9 months . | ||
| . | Major . | Complete . | Major . | Complete . |
| †Cytogenetic responses are reported at 6 and 9 months for comparative purposes. | ||||
| †† F. Guilhot, personal communication. | ||||
| Imatinib 400 mg 26 | 63% | 40% | 75% | 54% |
| Imatinib + PEG-IFN 36 | 76% | 44% | 86% | 48% |
| Imatinib + Ara-C†† | 74% | 57% | 80% | 57% |
| Imatinib 400 mg30 | 80% | 52% | ||
| Imatinib 800 mg30 | 83% | 65% | ||
| . | Cytogenetic Responses† . | |||
|---|---|---|---|---|
| . | 6 months . | 9 months . | ||
| . | Major . | Complete . | Major . | Complete . |
| †Cytogenetic responses are reported at 6 and 9 months for comparative purposes. | ||||
| †† F. Guilhot, personal communication. | ||||
| Imatinib 400 mg 26 | 63% | 40% | 75% | 54% |
| Imatinib + PEG-IFN 36 | 76% | 44% | 86% | 48% |
| Imatinib + Ara-C†† | 74% | 57% | 80% | 57% |
| Imatinib 400 mg30 | 80% | 52% | ||
| Imatinib 800 mg30 | 83% | 65% | ||